Resources from the same session
Controversy 1: Which are the biomarkers useful for molecular treatments?
Presenter: Jose Alejandro Pérez-Fidalgo
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Slides
Webcast
Controversy 2: which are the indications for chemo-radiotherapy?
Presenter: Stephanie de Boer
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Slides
Webcast
Controversy 3: which is the management of non-endometrioid histotypes?
Presenter: Nicoletta Colombo
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Slides
Webcast
ESMO CPG in endometrial cancer: which are the expected changes?
Presenter: Nicoletta Colombo
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Slides
Webcast
Conclusions
Presenter: Nicoletta Colombo
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Slides
Webcast
Live Q&A
Presenter: Cristiana Sessa
Session: ESMO Colloquium supported by Eisai: Controversies endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Resources:
Webcast